What is Embryo Glue?
In in vitro fertilization (IVF) treatment, embryo transfer represents a crucial step that influences the likelihood of pregnancy. EmbryoGlue, often referred to as "embryo glue," is a specialized transfer fluid utilized just prior to the embryo transfer. Despite its name containing "glue," it does not serve as a substance that physically adheres the embryo to the uterine wall.
| Concise overview EmbryoGlue is a transfer medium that is rich in hyaluronan (hyaluronic acid). Its purpose is to facilitate the implantation process by enhancing the interaction between the embryo and the uterine lining. Since evidence does not conclusively show benefits for all patients, the choice to utilize it should be assessed on a case-by-case basis. |
What is EmbryoGlue?
EmbryoGlue is a culture and transfer fluid rich in hyaluronan, which surrounds the embryo immediately prior to its transfer to the uterus. Hyaluronan is a naturally occurring molecule in the body and is also present in uterine fluid. Consequently, EmbryoGlue is designed to replicate certain features of the uterine environment.
What is it not?
It is not a mechanical adhesive that "binds" the embryo to the uterine wall.
It is not an independent surgical procedure that fundamentally alters the location or method of the transfer.
The main objective may be to facilitate the implantation process, which involves the embryo attaching and embedding itself in the uterine lining.
How can it be utilized?
When embryo transfer is scheduled, the embryo is momentarily positioned in this transfer medium that contains a high level of hyaluronan. Subsequently, it is introduced into the uterus through a slender catheter. For the majority of patients, the procedure feels largely similar to a standard transfer; it typically does not necessitate extra anesthesia or surgical intervention.
Overall process
The embryo is temporarily positioned in a medium similar to EmbryoGlue before transfer.
Embryo transfer into the uterus using a catheter.
The clinical protocol (medications/rest recommendations) must be maintained precisely as scheduled following the transfer.
Possible advantages
The primary expectation associated with EmbryoGlue is its potential to enhance clinical pregnancy and/or live birth rates by facilitating the implantation process. Although certain studies have indicated favorable outcomes, the results are varied; the degree of advantage has not been consistent across all research, and a clear, definitive benefit has yet to be established for all individuals.
Some independent evaluations characterize the level of evidence as “contradictory”; that is, although a benefit may be acknowledged in certain groups, a definitive superiority may not be established in the overall patient population. For instance, HFEA may categorize hyaluronate-rich transfer media as “amber/yellow” for numerous patients (signifying contradictory evidence).
| Not The response to the inquiry "Is there a benefit?" can differ based on factors including age, embryo quality, prior attempts, and the practices of the clinic. Consequently, outcomes may not be uniform across individuals. |
Are there any potential risks?
Current data indicate that hyaluronan-enriched transfer media are generally safe and do not present any significant additional risk to the mother or infant. However, as with any supplementary intervention, the decision should be evaluated alongside factors such as potential benefit uncertainty and cost.
Factors to take into account
Uncertainty regarding evidence — A clear advantage has not been shown for all patients.
Cost — Extra fees may be incurred; effective budget planning is essential.
Multiple pregnancy — Several publications have addressed the potential for a higher incidence of multiple pregnancies; consequently, clinics may especially emphasize the single embryo transfer method.
Who might this be applicable to?
EmbryoGlue may be routinely assessed in certain centers and in specific patients in others. It may be taken into account, particularly in the following circumstances, in consultation with the medical team:
Patients with a history of unsuccessful transfers (repeated unsuccessful attempts)
Circumstances in which implantation support is directed according to patient and embryo characteristics.
Scenarios considered suitable according to clinical methods and laboratory guidelines.
Nevertheless, robust and consistent evidence to conclusively determine that a specific treatment offers the most significant advantage for a particular patient group remains limited. Consequently, the most precise method is an individualized medical evaluation.
Conclusion
EmbryoGlue is not a product that "adheres" the embryo; it is a transfer fluid that contains hyaluronan (hyaluronic acid) designed to enhance specific characteristics of the intrauterine environment. Although the intention is to facilitate the implantation process, research findings are varied, and a clear, conclusive advantage for all individuals has not been established.
While EmbryoGlue is typically regarded as safe, the choice to utilize it should be determined on a case-by-case basis, in collaboration with the IVF specialist and embryology team. This decision should take into account factors such as age, embryo quality, past transfer outcomes, cost, and the clinic's expertise.
